Clinical Trials · NCT06829355
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Beijing Friendship Hospital
- Enrollment
- 52
- Start date
- Feb 2025
- Locations
- 1 site, China
- Primary endpoint
- Progression-free survival (PFS)